For example, dysregulation of SRC family kinases, mTOR, and p53 in CML cells has been reported, and these molecular pathways also mediate imatinib resistance [25–27]. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.